BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights IzoView Breast CT Advantages Over Existing Imaging Technologies

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based products for breast cancer detection and treatment, released an educational overview comparing its IzoView Breast CT Imaging System to current breast imaging technologies. IzoView offers true 3D, ultra-high-resolution imaging without breast compression and is designed to bridge the gap between digital breast tomosynthesis and MRI. Developed under a global license from UC Davis, IzoView delivers 100x greater spatial resolution than MRI at a lower cost and with shorter scan times, aiming to improve screening, diagnosis, and treatment planning, particularly in women with dense breast tissue.

To view the full press release, visit https://ibn.fm/VGTva

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca

For more information, visit the company’s website at https://izocorp.com/

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated…

2 days ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery 

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Bioscience announced key advancements in their global intellectual property portfolio supporting OT-101, a…

2 days ago

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox

NanoViricides, Inc. (NYSE American: NNVC) announced it has filed an application for Orphan Drug Designation…

2 days ago

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer…

3 days ago

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) to Report Fourth-Quarter 2025 Financial Results Feb. 17

Earth Science Tech (OTC: ETST), a strategic holding company focused on acquiring and scaling high-potential…

4 days ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics using proprietary intranasal delivery…

5 days ago